Search

This work focuses on applying a combined process combining electro-Fenton (EF) pretreatment with biological degradation to mineralize the antiviral Ribavirin in an efficient, economical and ecological manner. First, the main experimental parameters affecting the efficiency of the electro-Fenton process, namely applied current intensity, Fe(II) catalyst concentration and initial Ribavirin concentration were evaluated and optimized. Indeed, the mineralization rate reaches maximum residual values of 99% after 4 hours of electrolysis applying a current of 200 mA. This mineralization is accompanied by an increase in biodegradability, evaluated from the BOD5/COD ratio, which goes from 0.04 at the beginning of treatment (1 h) to 0.45 after 2 hours of electrolysis, demonstrating the feasibility of a biological treatment. In addition, the energy efficiency decreased when the treatment time was extended due to the limitation of mass transport. Thus, the feasibility of coupling electro-Fenton and biological treatment has been successfully demonstrated on a laboratory-scale was, achieving a 96.66% removal rate by the Bio-EF process. A Box-Behnken design based on response surface methodology was applied to develop a model for predicting Rib removal rate. The interaction of factors such as Rib concentration (X1), catalyst concentration (X2) and electrolysis time (X3) was analyzed to identify optimal operating conditions. The model results obtained are statistically significant with an R2 of 0.99, indicating that the proposed model is significant and relevant. In addition, the iso-response curves obtained enabled us to determine the optimal experimental conditions required for effective mineralization of the targeted antiviral. [ABSTRACT FROM AUTHOR]

The Electro-Fenton process is an electrochemical advanced oxidation method based on electrocatalytic in situ production of hydroxyl radicals (•OH). The decontamination of water polluted by Oxytetracycline (OTC) as being a toxic and persistent organic contaminant was carried out by the Electro-Fenton process (EF). Using a platinum anode and a carbon felt, many experiments have been carried out while studying the effect of several parameters on the efficiency of EF such as the applied current, the concentration of the catalyst, and the initial concentration of OTC. The degradation kinetics were studied and monitored by HPLC during electrolysis using an OTC initial concentration of 0.03 mM, 500 mA as applied current, and 0.1 mM of Fe2+ as optimal parameters. As for the mineralization, the chemical oxygen demand COD gave a reduction rate greater than 97% for 500 mA and 0.2 mM of Fe2+. The identification of some intermediate compounds was carried out by HPLC and LC-MS/MS. [ABSTRACT FROM AUTHOR]

The article is concerned the inverse problem for a mixed-type equation with power degeneracy on a transition line by definition of its right-hand side, depending on the spatial coordinate. A criterion for the uniqueness of the solution of the problem is established, providing that the solution itself is constructed in the form of a sum of orthogonal series. A justification is given for the convergence of series in the class of regular solutions of the given equation and the stability of the solution with respect to boundary functions has been proved. [ABSTRACT FROM AUTHOR]

AT7519M is a small molecule inhibitor of cyclin-dependent kinases 1, 2, 4, 5, and 9 within vitroactivity against lymphoid malignancies. In two concurrent Phase II trials, we evaluated AT7519M in relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) using the recommended Phase II dosing of 27 mg/m2twice weekly for 2 of every 3 weeks. Primary objective was objective response rate (ORR). Nineteen patients were accrued (7 CLL, 12 MCL). Four CLL patients achieved stable disease (SD). Two MCL patients achieved partial response (PR), and 6 had SD. One additional MCL patient with SD subsequently achieved PR 9 months after completion of AT7519M. Tumor lysis syndrome was not reported. In conclusion, AT7519M was safely administered to patients with relapsed/refractory CLL and MCL. In CLL, some patients had tumor reductions, but the ORR was low. In MCL, activity was noted with ORR of 27%. [ABSTRACT FROM PUBLISHER]

Background: Metformin may improve metabolic factors (insulin, glucose, leptin, highly sensitive C-reactive protein [hs-CRP]) associated with poor breast cancer outcomes. The NCIC Clinical Trials Group (NCIC CTG) MA.32 investigates effects of metformin vs placebo on invasive disease-free survival and other outcomes in early breast cancer. Maintaining blinding of investigators to outcomes, we conducted a planned, Data Safety Monitoring Committee-approved, analysis of the effect of metformin vs placebo on weight and metabolic factors at six months, including examination of interactions with baseline body mass index (BMI) and insulin, in the first 492 patients with paired blood samples. Methods: Eligible nondiabetic subjects with T1-3, N0-3, M0 breast cancer who had completed surgery and (neo)adjuvant chemotherapy (if given) provided fasting plasma samples at random assignment and at six months. Glucose was measured locally; blood was aliquoted, frozen, and stored at -80°C. Paired plasma aliquots were analyzed for insulin, hs-CRP, and leptin. Spearman correlation coefficients were calculated and comparisons analyzed using Wilcoxon signed rank test. All statistical tests were two-sided. Results: Mean age was 52.1 ±9.5 years in the metformin group and 52.6 ± 9.8 years in the placebo group. Arms were balanced for estrogen/progesterone receptor, BMI, prior (neo)adjuvant chemotherapy, and stage. At six months, decreases in weight and blood variables were statistically significantly greater in the metformin arm (vs placebo) in univariate analyses: weight -3.0%, glucose -3.8%, insulin -11.1%, homeostasis model assessment -17.1%, leptin -20.2%, hs-CRP -6.7%; all P values were less than or equal to .03. There was no statistically significant interaction of change in these variables with baseline BMI or insulin. Conclusions: Metformin statistically significantly improved weight, insulin, glucose, leptin, and CRP at six months. Effects did not vary by baseline BMI or fasting insulin. [ABSTRACT FROM AUTHOR]

Background: Metformin may improve metabolic factors (insulin, glucose, leptin, highly sensitive C-reactive protein [hs-CRP]) associated with poor breast cancer outcomes. The NCIC Clinical Trials Group (NCIC CTG) MA.32 investigates effects of metformin vs placebo on invasive disease-free survival and other outcomes in early breast cancer. Maintaining blinding of investigators to outcomes, we conducted a planned, Data Safety Monitoring Committee-approved, analysis of the effect of metformin vs placebo on weight and metabolic factors at six months, including examination of interactions with baseline body mass index (BMI) and insulin, in the first 492 patients with paired blood samples.Methods: Eligible nondiabetic subjects with T1-3, N0-3, M0 breast cancer who had completed surgery and (neo)adjuvant chemotherapy (if given) provided fasting plasma samples at random assignment and at six months. Glucose was measured locally; blood was aliquoted, frozen, and stored at -80°C. Paired plasma aliquots were analyzed for insulin, hs-CRP, and leptin. Spearman correlation coefficients were calculated and comparisons analyzed using Wilcoxon signed rank test. All statistical tests were two-sided.Results: Mean age was 52.1±9.5 years in the metformin group and 52.6 ± 9.8 years in the placebo group. Arms were balanced for estrogen/progesterone receptor, BMI, prior (neo)adjuvant chemotherapy, and stage. At six months, decreases in weight and blood variables were statistically significantly greater in the metformin arm (vs placebo) in univariate analyses: weight -3.0%, glucose -3.8%, insulin -11.1%, homeostasis model assessment -17.1%, leptin -20.2%, hs-CRP -6.7%; all P values were less than or equal to .03. There was no statistically significant interaction of change in these variables with baseline BMI or insulin.Conclusions: Metformin statistically significantly improved weight, insulin, glucose, leptin, and CRP at six months. Effects did not vary by baseline BMI or fasting insulin. [ABSTRACT FROM AUTHOR]